Hein Matthieu, Bouchart Christelle
Service de Psychiatrie et Laboratoire du Sommeil, CHU Brugmann, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.
Laboratoire de Psychologie Médicale et Addictologie (ULB312), Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.
Curr Oncol. 2025 Sep 13;32(9):511. doi: 10.3390/curroncol32090511.
The literature provides evidence of the negative impact of depression on mortality among cancer patients. Depression is also a common comorbidity in pancreatic cancer (PC). The objective of this systematic review was to provide a state-of-the-art overview of the potential role of depression in the excess mortality observed in patients with PC. Based on PRISMA guidelines, a systematic review (PROSPERO: CRD420251135451) was conducted in August 2025 using the Pubmed-Medline and Scopus database. After assessment by two readers of the 325 identified articles, 8 articles ( = 143,033) published between 1 January 2010 and 15 August 2025 investigating the specific impact of depression (diagnosed by psychiatric interviews, self-report questionnaires, or diagnostic codes) on mortality in patients with PC (diagnosed by clinical diagnosis or diagnostic codes) were included in this systematic literature review. Articles that were not research studies and were written in a language other than English/French were not included. Risk of bias was assessed using the ROBINS-I tool. A narrative synthesis of the results was performed for the potential impact of depression on mortality in patients with PC. The reported prevalence of depression in this population ranged from 7.4% to 51.8% (seven studies, = 142,983), depending on the studies considered. Most of the included studies (seven studies, = 141,728) consistently reported an increased risk of mortality associated with depression, regardless of cancer stage or treatment received. However, the scientific quality of these studies was generally low, with a significant risk of bias. These results suggest that better integration of depression management in the care of patients with PC could potentially improve clinical outcomes in this high-risk population.
文献提供了抑郁症对癌症患者死亡率产生负面影响的证据。抑郁症也是胰腺癌（PC）中常见的合并症。本系统评价的目的是全面概述抑郁症在PC患者观察到的额外死亡率中可能发挥的作用。根据PRISMA指南，于2025年8月使用Pubmed-Medline和Scopus数据库进行了一项系统评价（PROSPERO：CRD420251135451）。在两名读者对325篇已识别文章进行评估后，纳入了8篇（n = 143,033）在2010年1月1日至2025年8月15日期间发表的研究，这些研究调查了抑郁症（通过精神科访谈、自我报告问卷或诊断编码诊断）对PC患者（通过临床诊断或诊断编码诊断）死亡率的具体影响。非研究性文章以及非英文/法文撰写的文章均未纳入。使用ROBINS-I工具评估偏倚风险。对抑郁症对PC患者死亡率的潜在影响进行了叙述性结果综合分析。根据所考虑的研究，该人群中报告的抑郁症患病率在7.4%至51.8%之间（七项研究，n = 142,983）。大多数纳入研究（七项研究，n = 141,728）一致报告，无论癌症分期或接受的治疗如何，抑郁症都会增加死亡风险。然而，这些研究的科学质量普遍较低，存在显著的偏倚风险。这些结果表明，在PC患者的护理中更好地整合抑郁症管理可能会改善这一高危人群的临床结局。
